Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H16N2O2.H2O |
| Molecular Weight | 214.2615 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O=C([C@H]1CCC(=O)N1)N2CCCCC2
InChI
InChIKey=YUBYMONBCDIKAB-DDWIOCJRSA-N
InChI=1S/C10H16N2O2.H2O/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12;/h8H,1-7H2,(H,11,13);1H2/t8-;/m1./s1
DescriptionCurator's Comment: description was created based on several sources, including, https://www.nootropics.eu/a-review-on-the-benefits-of-fasoracetam/
Curator's Comment: description was created based on several sources, including, https://www.nootropics.eu/a-review-on-the-benefits-of-fasoracetam/
Fasoracetam is a cognition enhancer that interacts with GABA(B) receptors, stimulates neuronal ACh receptors and modulates mGlu receptors. The drug is being tested in phase III/II of clinical trials for the treatment of Attention Deficit Disorder With Hyperactivity in people with genetic disorders impacting mGlu receptors and never been approved by FDA. Fasoracetam is also being marketed in the form of capsules for research purposes aimed at investigation of cognition and memory disorders.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2111463 |
|||
Target ID: Acetylcholine receptor |
|||
Target ID: Metabotropic glutamate receptors Sources: http://www.medgenics.com/c/pipeline/ |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. | 1997 Apr 18 |
|
| A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture. | 1997 Aug |
|
| Fasoracetam. LAM 105, NS 105. | 1999 Aug |
Patents
Sample Use Guides
100, 200, or 400 mg twice daily as capsules for oral administration.
Route of Administration:
Oral
Fasoracetam (10(-7) and 10(-6) M) inhibited forskolin-stimulated cyclic AMP formation in cultured neurons of the mouse cerebral cortex. Conversely, in pertussis toxin-pretreated neurons, the drug (10(-7)-10(-5) M) significantly enhanced the forskolin-stimulated cyclic AMP formation, and this action was completely reversed by cholera toxin.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
55BRM1BEZN
Created by
admin on Sat Dec 16 05:27:10 GMT 2023 , Edited by admin on Sat Dec 16 05:27:10 GMT 2023
|
PRIMARY | |||
|
10198262
Created by
admin on Sat Dec 16 05:27:10 GMT 2023 , Edited by admin on Sat Dec 16 05:27:10 GMT 2023
|
PRIMARY | |||
|
2055646-53-0
Created by
admin on Sat Dec 16 05:27:10 GMT 2023 , Edited by admin on Sat Dec 16 05:27:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
